At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
LL-BMT1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Study of Safety, Tolerability, and Efficacy of Drug-Delivering Contact Lens LL-BMT1 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 2 clinical trial evaluating LL-BMT1 for Primary Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Open Angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartJan 2021
First PostedFeb 2021
Primary CompletionFeb 2021
TodayJul 2026
First PostedFeb 10, 2021
Enrollment StartJan 8, 2021
Primary CompletionFeb 16, 2021
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 5.4 years ago
Interventions
LL-BMT1drug
Drug-printed contact lens in both eyes